Hum Vaccin Immunother: Persistence of immune response after 4CMenB vaccination

Multi-component meningoccal serogroup B vaccine 4CMenB has been shown to be effective in preventing invasive MenB disease in infants and controlling MenB outbreaksNo additional enhanced dose/timing has been determined
We reviewed eight studies that evaluated the persistence and enhancement of antibodies after the initial 4CMenB vaccination in infants, children, adolescents and adolescents
The results showed that between 24 and 36 months after the initial infancy, 76-100% of children maintained the assumed serum-protective hSBA titer of the vaccine antigen, while after the first vaccination of the second time in life, it remained at 84-100%Four and 7.5 years after the beginning of puberty, hSBA levels in the vaccine were higher than in the unvaccinated age groupAntibodies are more persistent to NHBA and NadA than to PorA or fHbpEnhanced vaccination can cause a strong memory cancellation response, proving that 4CMenB can be effective in everyone at different ages
These data can provide a basis for decision-making to optimize vaccination strategies